Inovio Pharma (INO)

$1.09 +0.04 (3.81%)
Market Cap 78.07M
Revenue (ttm) 70,000.00
Net Income (ttm) -84.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -121,357.14%
Debt to Equity Ratio 0.00
Volume 2,986,266
Avg Vol 1,391,848
Day's Range N/A - N/A
Shares Out 69.09M
Stochastic %K 0%
Beta 1.70
Analysts Strong Sell
Price Target $7.63

Company Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 440 4200
Address:
660 West Germantown Pike, Suite 110, Plymouth Meeting, United States
GorillaofWallStreet
GorillaofWallStreet Apr. 8 at 8:22 PM
$INO
0 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 8 at 8:03 PM
$INO congrats on the big day today fellas! Approximately 4,500 more like today and y’all will be back to even!
1 · Reply
wallstbullinfinity
wallstbullinfinity Apr. 8 at 7:59 PM
$INO Iono, I'm still waiting for under a dollar because every time I drop a bag and buy big... randomly, the price becomes what i should've/ could've bought. Either way up or down I'm winning this time. Our day is coming, all bases are loaded
0 · Reply
lolord
lolord Apr. 8 at 7:49 PM
$INO
0 · Reply
Iluvfor30s
Iluvfor30s Apr. 8 at 7:35 PM
$INO YES!!!!!
0 · Reply
HARM20
HARM20 Apr. 8 at 5:53 PM
$INO Bullish!
0 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 8 at 5:15 PM
$INO you guys rich yet?
0 · Reply
tau72
tau72 Apr. 8 at 4:23 PM
$INO Let's us vote against all BoD and reduce the # of executives and all or most of their compensation...Too many of them and too much comparing to what they've been achieved...
0 · Reply
RajCx
RajCx Apr. 8 at 4:11 PM
$INO So close to 1$. They are just toying with us here. We can easily delist from here. PLEASE stand together and do not approve another RS if it comes to that. Delisting is not necessarily bad while we wait for news. Anyone who says this round of dilution was no biggy is so wrong! Convert this dilution to before RS and you will understand the gravity of this situation. And what did they get from this? Maybe one extra quarter? Do not understand such high sustained burn rate with nothing positive to share with shareholders. IMO we have already spent a fortune on getting commercialization ready without having a commercial product! Preparing is wise but to what level of spending? I also understand we just need that one win to turn around, but man I am getting tired of the dangled carrot(s)... Rant over and now I will just keep quiet and sign off and leave this to God. erm not God maybe FDA. lol!
1 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 8 at 3:54 PM
$INO fun fact, did you guys know ino-3107 was named after the year Shea estimates it will be approved? Year 3107 can’t come soon enough, amirite?😂😂😂😂only an idiot would put any money into this turd of a company
1 · Reply
Latest News on INO
INOVIO Announces Pricing of $17.5 Million Public Offering

Apr 2, 2026, 8:55 AM EDT - 6 days ago

INOVIO Announces Pricing of $17.5 Million Public Offering

INOVIO Announces Proposed Public Offering

Apr 1, 2026, 8:05 PM EDT - 6 days ago

INOVIO Announces Proposed Public Offering

INOVIO to Participate in Upcoming Scientific Conference

Apr 1, 2026, 10:29 AM EDT - 7 days ago

INOVIO to Participate in Upcoming Scientific Conference

Inovio Stock Up On Earnings, Pipeline Progress

Mar 13, 2026, 10:32 AM EDT - 26 days ago

Inovio Stock Up On Earnings, Pipeline Progress

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 12, 2026, 4:05 PM EDT - 27 days ago

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

INOVIO to Participate in Upcoming Scientific Conferences

Mar 9, 2026, 8:05 AM EDT - 4 weeks ago

INOVIO to Participate in Upcoming Scientific Conferences

INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Mar 5, 2026, 4:05 PM EST - 4 weeks ago

INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

Mar 4, 2026, 8:52 AM EST - 5 weeks ago

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

Mar 4, 2026, 8:05 AM EST - 5 weeks ago

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Feb 12, 2026, 8:05 AM EST - 7 weeks ago

INOVIO to Participate in Upcoming Scientific and Investor Conferences

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Dec 29, 2025, 8:05 AM EST - 3 months ago

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO Reports Inducement Grant Under Inducement Plan

Dec 19, 2025, 4:05 PM EST - 3 months ago

INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO to Participate in December Investor Conferences

Nov 18, 2025, 8:05 AM EST - 5 months ago

INOVIO to Participate in December Investor Conferences

INOVIO Announces Pricing of $25 Million Public Offering

Nov 11, 2025, 8:40 AM EST - 5 months ago

INOVIO Announces Pricing of $25 Million Public Offering

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 10, 2025, 4:05 PM EST - 5 months ago

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

Nov 3, 2025, 8:05 AM EST - 5 months ago

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

Oct 27, 2025, 8:05 AM EDT - 5 months ago

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Oct 23, 2025, 4:05 PM EDT - 5 months ago

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

Oct 21, 2025, 8:05 AM EDT - 6 months ago

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

Aug 26, 2025, 8:05 AM EDT - 8 months ago

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:05 AM EDT - 8 months ago

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 12, 2025, 4:05 PM EDT - 8 months ago

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Aug 11, 2025, 8:05 AM EDT - 8 months ago

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

Aug 4, 2025, 4:05 PM EDT - 8 months ago

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

INOVIO to Present at Upcoming Scientific Conference

Jul 7, 2025, 4:05 PM EDT - 9 months ago

INOVIO to Present at Upcoming Scientific Conference

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

Jul 1, 2025, 7:00 AM EDT - 10 months ago

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 13, 2025, 4:05 PM EDT - 11 months ago

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

INOVIO to Present at Upcoming Scientific and Investor Conferences

Apr 30, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific and Investor Conferences

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 29, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

INOVIO to Present at Upcoming Scientific Conferences

Apr 9, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific Conferences

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 18, 2025, 4:05 PM EDT - 1 year ago

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Mar 13, 2025, 6:15 PM EDT - 1 year ago

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Mar 12, 2025, 12:55 PM EDT - 1 year ago

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Feb 12, 2025, 8:00 AM EST - 1 year ago

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Feb 10, 2025, 8:05 AM EST - 1 year ago

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 4:14 PM EST - 1 year ago

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Jan 9, 2025, 8:04 AM EST - 1 year ago

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

GorillaofWallStreet
GorillaofWallStreet Apr. 8 at 8:22 PM
$INO
0 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 8 at 8:03 PM
$INO congrats on the big day today fellas! Approximately 4,500 more like today and y’all will be back to even!
1 · Reply
wallstbullinfinity
wallstbullinfinity Apr. 8 at 7:59 PM
$INO Iono, I'm still waiting for under a dollar because every time I drop a bag and buy big... randomly, the price becomes what i should've/ could've bought. Either way up or down I'm winning this time. Our day is coming, all bases are loaded
0 · Reply
lolord
lolord Apr. 8 at 7:49 PM
$INO
0 · Reply
Iluvfor30s
Iluvfor30s Apr. 8 at 7:35 PM
$INO YES!!!!!
0 · Reply
HARM20
HARM20 Apr. 8 at 5:53 PM
$INO Bullish!
0 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 8 at 5:15 PM
$INO you guys rich yet?
0 · Reply
tau72
tau72 Apr. 8 at 4:23 PM
$INO Let's us vote against all BoD and reduce the # of executives and all or most of their compensation...Too many of them and too much comparing to what they've been achieved...
0 · Reply
RajCx
RajCx Apr. 8 at 4:11 PM
$INO So close to 1$. They are just toying with us here. We can easily delist from here. PLEASE stand together and do not approve another RS if it comes to that. Delisting is not necessarily bad while we wait for news. Anyone who says this round of dilution was no biggy is so wrong! Convert this dilution to before RS and you will understand the gravity of this situation. And what did they get from this? Maybe one extra quarter? Do not understand such high sustained burn rate with nothing positive to share with shareholders. IMO we have already spent a fortune on getting commercialization ready without having a commercial product! Preparing is wise but to what level of spending? I also understand we just need that one win to turn around, but man I am getting tired of the dangled carrot(s)... Rant over and now I will just keep quiet and sign off and leave this to God. erm not God maybe FDA. lol!
1 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 8 at 3:54 PM
$INO fun fact, did you guys know ino-3107 was named after the year Shea estimates it will be approved? Year 3107 can’t come soon enough, amirite?😂😂😂😂only an idiot would put any money into this turd of a company
1 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 8 at 3:01 PM
$INO stfu Robert you tool. This thing is only going one place. The shitter. Just like your investment “career”
1 · Reply
HARM20
HARM20 Apr. 8 at 2:07 PM
$INO Primed for a big breakout. Let’s get the party started.
1 · Reply
g82
g82 Apr. 8 at 1:30 PM
$INO Missed out on yesterday's bonanza. Let see what bargains we can get today
0 · Reply
23Cazzy
23Cazzy Apr. 8 at 10:34 AM
$INO Avoid Bentley posts! Been regurgitating the same crap for six years at least . Big time pumper!
1 · Reply
DragonAlgo
DragonAlgo Apr. 8 at 8:41 AM
🐉 $INO PUT — DragonAlgo® Signal Contract: INO PUT Expiry: 2026-04-10 | Strike: $1.00 | Type: PUT Option Plan (premium): Entry: $0.03 Stop: $0.02 TP1: $0.04 TP2: $0.05 TP3: $0.07 🔗 https://dragonalgo.com
0 · Reply
Bio_Be_Dirty
Bio_Be_Dirty Apr. 8 at 5:47 AM
$INO hear me DNA it’s the best vaccine out there
1 · Reply
updownsides
updownsides Apr. 8 at 1:43 AM
$INO Yes Buttley. The whole existence of Inovio is all about ino-3107. Everyone knows this. Dr. Shea knows. Every single bagholder knows except you.
0 · Reply
INOxray8
INOxray8 Apr. 8 at 1:00 AM
$INO TACO Tuesday https://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/799a9b06-a9b5-4959-8266-6c8f417d05de.pdf
0 · Reply
rioe
rioe Apr. 8 at 12:12 AM
$INO Tomorrow’s shaping up to be a strong day! With funding now secured through FDA approval and beyond, we’re in a solid position. Onward and upward! 🚀🚀🚀
2 · Reply
BentleyT99
BentleyT99 Apr. 7 at 10:54 PM
$INO News Pending IMHO
0 · Reply
YouGuysHateMoney
YouGuysHateMoney Apr. 7 at 9:38 PM
$INO for those new here this asshol* buttley has been saying the same stuff for years and is most likely paid by the company to do so. He is a shill that shouldn’t be trusted
0 · Reply
RajCx
RajCx Apr. 7 at 8:38 PM
$INO Annual proxy out just now. Hurts looking at their compensations! 😭
1 · Reply